BMS-936558 is an antibody against PD-1, a protein involved in repressing the immune system. It activates the immune system and enables it to fight tumors. A well established approved drug, Yervoy blocks CTLA-4, another inhibitory protein expressed on immune cells and Yervoy and BMS-936558 belong to the same class of drugs. Both generate an anti-cancer immune response.
This very promising agent is in several trials for various diagnoses. For example, for renal cancer there is the Phase II trial of BMS-936558 (MDX-1106) in Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Tx and CA209-009 biolarker trial. There are also combination studies with various malignancies. It is a promising agent but still investigational.
Read the Professional version here.